# Long Term Safety Study of PRALUENT

> **NCT03694197** · PHASE4 · TERMINATED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 1389 (actual)

## Conditions studied

- Heterozygous Familial Hypercholesterolemia
- Non-familial Hypercholesterolemia

## Interventions

- **DRUG:** Praluent

## Key facts

- **NCT ID:** NCT03694197
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-28
- **Primary completion:** 2020-04-08
- **Final completion:** 2020-04-08
- **Target enrollment:** 1389 (ACTUAL)
- **Why stopped:** The primary objective (to evaluate the long-term safety of Praluent) was adequately evaluated in other studies.
- **Last updated:** 2021-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03694197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03694197, "Long Term Safety Study of PRALUENT". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03694197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*